首页> 外文OA文献 >PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT: A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

【2h】

PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT: A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

机译：PCN3 - 现实世界的转移性乳腺癌治疗证据：帕尔比霉素治疗与内分泌治疗之间的不良反应比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
S. Kuranz;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2-metastatic breast cancer patients: The PALPract study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：帕尔博昔米菌加入内分泌治疗的实际验证和活性证据和HR + / HER2-转移性乳腺癌患者的进展后治疗：PALPRACT研究
2. Interview for Breast Cancer Management with Dr David Montgomery: marketing authorization for Pfizer's metastatic breast cancer treatment, palbociclib (Ibrance?) in combination with endocrine therapy [J] . David Montgomery Breast cancer management. . 2016,第3a4期

机译：采访乳腺癌管理与David Montgomery博士：普遍促销乳腺癌治疗的营销授权，Palbociclib（Ibrance？）与内分泌治疗组合
3. Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Palbociclib与Trastuzumab和内分泌治疗（ET）与医生的选择（TPC）与PAM50腔内在亚型（Solti-1303 Patricia II）的乳腺癌（Solti-1303）的乳腺癌（Solti-1303）：A 多中心，随机，开放标签，第二阶段试验
4. Pharmacology of photosensitiser in rats with metastatic breast cancer - time point determination for photodynamic therapy treatment (PDT) of vertebral metastases - [C] . Margarete K. Akens, Albert J.M. Yee, Lothar Lilge, Photonic Applications in Biosensing and Imaging; Progress in Biomedical Optics and Imaging; vol.6 no.39 . 2005

机译：光敏剂在转移性乳腺癌大鼠中的药理作用-椎骨转移瘤光动力疗法治疗（PDT）的时间点确定-
5. Analysis of the Quality of Oral Antineoplastic Prescription Data for Use in Real-World Evidence: Palbociclib in Metastatic Breast Cancer as a Use Case [D] . Wilson, Natalie Ann. 2020

机译：用于现实世界证据的口腔抗肿瘤处方数据质量分析：帕尔巴昔米菌在转移性乳腺癌中作为用例
6. Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China [O] . Chang Liu, Ting Li, Zhonghua Tao, 2020

机译：用Palbociclib加内分泌治疗和随后治疗治疗130例激素受体阳性和人表皮生长因子受体2阴性转移性乳腺癌患者的临床结果和疗法：中国的真实单中心回顾性研究
7. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study [O] . Raffaella Palumbo, Rosalba Torrisi, Federico Sottotetti, 2021

机译：激素受体阳性/ HER2受体 - 阴性转移乳腺癌中Palbociclib Plus内分泌治疗的治疗和结果模式：真实世界的Multicentre Italial研究

PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT: A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

著录项

引文网络

相似文献

相关主题

期刊订阅